AbCheck and Pierre Fabre Enter Into Strategic Research Partnership

Under the expanded agreement, AbCheck will use its proprietary human antibody discovery and optimization platform technologies, AbSieve and AbAccel, to deliver antibodies against two or more targets provided by Pierre Fabre per year over a period of three years. This period can be extended to up to five years. Pierre Fabre has secured full rights to all antibodies selected in exchange for discovery fees and milestone payments to AbCheck.

AbCheck is recognized for its expertise in human antibody discovery and optimization throughout the U.S. and Europe. Pierre Fabre, the third largest French pharmaceutical company, has a long-standing commitment to oncology and immunology. The Pierre Fabre Immunology Centre (CIPF) in Saint-Julien-en-Genevois, France, is dedicated to the identification, development and manufacturing of therapeutic monoclonal antibodies in focused therapeutic areas.

“We are extremely pleased that our technology platform, performance and business attitude has encouraged Pierre Fabre to select AbCheck as its main provider for therapeutic antibodies,” said Volker Lang, managing director, AbCheck.

“At Pierre Fabre Immunology Center, we are working on a wide range of new promising targets and are always looking to reinforce our capabilities through collaborations with world-class platforms. This strategic partnership with AbCheck will support and accelerate our antibody discovery,” said Nathalie Corvaïa, managing director, Pierre Fabre Immunology Center.